BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman Sells 987 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 987 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the sale, the chief financial officer now directly owns 121,779 shares in the company, valued at $3,290,468.58. The trade was a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, November 26th, Troy Wichterman sold 581 shares of BioLife Solutions stock. The stock was sold at an average price of $27.20, for a total transaction of $15,803.20.
• On Tuesday, November 12th, Troy Wichterman sold 147 shares of BioLife Solutions stock. The stock was sold at an average price of $26.19, for a total value of $3,849.93.
• On Wednesday, October 30th, Troy Wichterman sold 894 shares of BioLife Solutions stock. The shares were sold at an average price of $23.15, for a total value of $20,696.10.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS opened at $26.61 on Friday. The firm has a market capitalization of $1.23 billion, a P/E ratio of -25.10 and a beta of 1.92. The firm’s 50-day moving average price is $25.99 and its 200-day moving average price is $24.29. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 1-year low of $14.50 and a 1-year high of $28.88.

Wall Street Analyst Weigh In

BLFS has been the topic of several analyst reports. Craig Hallum upped their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Northland Securities increased their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday. TD Cowen boosted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. KeyCorp increased their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Finally, HC Wainwright dropped their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.43.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BLFS. Fred Alger Management LLC grew its stake in BioLife Solutions by 6.0% in the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after acquiring an additional 88,840 shares during the period. State Street Corp grew its position in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after purchasing an additional 95,788 shares during the period. Geode Capital Management LLC increased its stake in BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after purchasing an additional 18,473 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in BioLife Solutions by 9.1% during the second quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock worth $17,034,000 after buying an additional 66,422 shares during the last quarter. Finally, Rockefeller Capital Management L.P. lifted its stake in shares of BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock valued at $14,661,000 after buying an additional 262,504 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.